DESIGN THERAPEUTICS INC. - COMMON STOCK
4.1050
14-February-25 11:08:53
15 minutes delayed
Stocks
+0.1350
+3.40%
Today's range
3.9050 - 4.1900
ISIN
N/A
Source
NASDAQ
-
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
08 Aug 2022 16:05:01 By Nasdaq GlobeNewswire
-
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
03 Aug 2022 06:30:00 By Nasdaq GlobeNewswire
-
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 06:30:00 By Nasdaq GlobeNewswire
-
09 May 2022 16:05:01 By Nasdaq GlobeNewswire
-
30 Mar 2022 06:30:00 By Nasdaq GlobeNewswire
-
10 Mar 2022 16:02:00 By Nasdaq GlobeNewswire
-
09 Mar 2022 06:30:00 By Nasdaq GlobeNewswire
-
28 Feb 2022 16:05:00 By Nasdaq GlobeNewswire
-
Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
10 Feb 2022 06:30:00 By Nasdaq GlobeNewswire
-
Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
01 Feb 2022 16:05:01 By Nasdaq GlobeNewswire
-
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results
09 Nov 2021 16:05:01 By Nasdaq GlobeNewswire
-
08 Sep 2021 06:30:00 By Nasdaq GlobeNewswire
-
Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results
09 Aug 2021 16:05:00 By Nasdaq GlobeNewswire
-
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
07 Jun 2021 16:10:00 By Nasdaq GlobeNewswire
-
Design Therapeutics Expands Board of Directors with Key Appointments
07 Jun 2021 16:05:00 By Nasdaq GlobeNewswire
-
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
10 May 2021 16:05:00 By Nasdaq GlobeNewswire